Abstract B003: Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma
Bibliographic record
Abstract
Abstract The immunosuppressive tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major factor that limits the therapeutic effect of immunotherapy and chemotherapy in PDAC patients. A promising approach is the use of oncolytic viruses (OVs), particularly the vesicular stomatitis virus (VSVd51), which has been shown to have an increased cytotoxicity on PDAC cells while sparing healthy cells. Additionally, enhancing OVs with immune-stimulating cytokines has shown great promise in cold tumors such as PDAC because of its ability to potentiate antitumor immune responses. Our study aims to modulate the PDAC TME using an oncolytic virus armed with the pro-inflammatory cytokine tumor-necrosis factor superfamily member 14 (VSVd51-LIGHT). In our orthotopic mouse model of PDAC, murine pancreatic KPC cancer cell lines were implanted orthotopically into the pancreas of immune-competent mice. Mice were treated intraperitoneally with VSVd51-LIGHT, Folfirinox, or a combination of both therapies. Notably, a synergistic effect was observed when VSVd51-LIGHT was combined with chemotherapy, extending the median mice survival from 34 to 42 days. In parallel, the antitumor immune response was assessed using flow cytometry and IFNγ ELISpot. A significant increase (>20%) of tumor infiltrating CD8+ T cells and effector functions (GZMB+) was observed in the combination-treated cohorts. Additionally, a 5-fold increase in IFNγ producing CD8+ T cells was detected against irradiated KPC cells in combination-treated mice. Altogether, these findings support the potential of VSVd51-LIGHT as a promising immunotherapeutic agent for treating PDAC. Citation Format: Jacob L. Leger, Nawal Amhis, Sarah Mansouri, Maxime Léveillé, Lauren Daniel, Hugo Giguère, Zoé Gerber, Gabriel St-Laurent, Maryline Labrie, Taha Azad, Yves Collin, Lee-Hwa Tai. Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B003.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".